Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

NCT04657198 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
126
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

GlaxoSmithKline